Organ-specific irAEs differed between the two agents; anti-PD1 treatment was complicated more frequently with arthritis, pneumonitis, myocarditis, thyroiditis and hematologic toxicities, whereas anti-CTLA4-driven toxicities included colitis, hypophysitis and skin rash. Here, PDCD1 is linked to arthritic joint disease.